What does cough, cold & allergy — total revenues mean?

This metric represents the total net sales generated from the company's portfolio of over-the-counter cough, cold, and allergy relief products. It reflects the revenue performance of a specific consumer health category that is often subject to seasonal demand fluctuations and competitive market dynamics. Tracking this revenue stream helps investors assess the brand strength and market penetration of the company's respiratory and allergy-related product offerings.

Prestige Consumer Healthcare (PBH) Cough, Cold & Allergy — Total revenues

Screener

Other product segments

Gastrointestinal

$62.2M+7.6%

Women's Health

$52.54M-3.7%

Dermatologicals

$33.2M+10.2%

Eye & Ear Care

$32.98M+2.1%

Pain Relief

$26.8M—

Oral Care

$22.36M+3.0%

Wellness, Sleep & Other

$14.33M—

Similar metrics at other companies

SNDAResident revenue — Total revenues

$108.43M+36.8%

ASSTOther revenue — Total revenues

$43K+514%

ALN

ALNYRoyalty revenue — Total revenues

$71.67M+79.3%

HContra revenue — Total revenues

-$17M-13.3%

FTAIMaintenance revenue — Total revenues

$30.6M-38.3%

FTAIOther revenue — Total revenues

$6.21M+19,923%

Other financials

Income statement

See full

Revenue$265.7M+6.5%

Gross profit$136.2M-3.0%

Operating income$52.5M-26.8%

Net income$29.2M-38.5%

EPS (diluted)$0.61-35.8%

Balance sheet

See full

Cash & equivalents$89.1M-36.1%

Total debt$2.1B+97.4%

Total equity$1.9B+3.3%

Total assets$4.6B+33.1%

Cash flow

See full

Operating cash flow$70.8M-10.4%

CapEx$3.7M+342%

Free cash flow$67.1M-14.2%

Valuation

See full

Market cap$2.58B-30.3%

Enterprise value$4.55B-1.2%

P/E15×-2.4×

P/S2.3×-1.0×

Profitability

See full

Gross margin53.5%-2.6pp

Operating margin26.3%-3.8pp

Net margin15.6%-3.4pp

FCF margin21.3%-2.6pp

Returns & leverage

See full

Return on equity9.1%-2.9pp

Debt / equity1.1×+0.5×

Current ratio3.2×-1.2×

Where this comes from

Reported directly by Prestige Consumer Healthcare in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Prestige Consumer Healthcare’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 6:15 AM EDT
Fiscal quarter: Q1 FY2027
Calendar quarter: Q2 2026
Accession: 0001295947-26-000042

(In thousands)	Three Months Ended June 30, 2026 / North American OTCHealthcare	Three Months Ended June 30, 2026 / International OTCHealthcare	Consolidated
Cough, Cold & Allergy	$15,628	$5,677	$21,305
Dermatologicals	30,615	2,580	33,195
Eye & Ear Care	28,339	4,639	32,978
Gastrointestinal	47,141	15,061	62,202
Oral Care	18,458	3,900	22,358
Pain Relief	26,225	577	26,802
Wellness, Sleep & Other	12,559	1,768	14,327
Women's Health	47,241	5,302	52,543

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Prestige Consumer Healthcare's cough, cold & allergy — total revenues?: Prestige Consumer Healthcare (PBH) reported cough, cold & allergy — total revenues of $21.31M in Q2 2026.
What does cough, cold & allergy — total revenues mean?: This metric represents the total net sales generated from the company's portfolio of over-the-counter cough, cold, and allergy relief products. It reflects the revenue performance of a specific consumer health category that is often subject to seasonal demand fluctuations and competitive market dynamics. Tracking this revenue stream helps investors assess the brand strength and market penetration of the company's respiratory and allergy-related product offerings.